Lilly buddies up with Elektrofi on subcutaneous delivery of biologics

24 Oct 2023
·
Deals
firstwordpharma.com
License out/in
Eli Lilly entered into a research collaboration and license agreement with Elektrofi focused on developing next-generation medicines that can be delivered subcutaneously, the latter announced Tuesday. Elektrofi’s technology is designed to allow the at-home subcutaneous self-administration of biologic therapies.
Under the deal, Eli Lilly will make an upfront payment of $20 million for exclusive rights to three targets. Elektrofi is eligible to receive over $150 million in milestones for each target, as well as tiered sales royalties up to a mid-single digit.
Eli Lilly will be responsible for clinical development and commercialisation of each product, while it has the option to expand the agreement to up to two additional targets for additional payments. Elektrofi CEO Chase Coffman said the collaboration “further validates the potential value of our…technology platform, especially in the areas of autoimmune disease, oncology and neuroscience.”
Elektrofi’s ultra-high concentration microparticle suspension technology platform aims to resolve the limitations associated with intravenously biologic therapies, with a focus on monoclonal antibodies, therapeutic proteins and other large molecule drugs.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.